Not Yet RecruitingNot Applicable

PACE-AF: Prospective Analysis of Cardiac Electrostimulation and Atrial Fibrillation

Russia500 participantsStarted 2025-12

Plain-language summary

PACE-AF is a prospective, observational patient registry designed to evaluate the impact of pacemaker algorithms on atrial fibrillation (AF) incidence, progression, and clinical outcomes in patients implanted with dual-chamber pacemakers. The registry aims to include 400-500 patients with longitudinal follow-up. Primary outcomes are progression to permanent AF and all-cause mortality. Secondary outcomes include quality of life, hospitalization, and cardiovascular events.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * • Age ≥ 18 years * Implantation of a dual-chamber permanent pacemaker * Ability to provide informed consent * Willingness to participate in long-term follow-up Exclusion Criteria: * • Single-chamber pacemaker or Cardiac Resynchronization Therapy device at baseline * Life expectancy \< 1 year due to non-cardiac comorbidities * Inability to comply with follow-up visits or device interrogation * Participation in another clinical trial that could interfere with study endpoints

What they're measuring

Incidence of Permanent Atrial Fibrillation (%)

Timeframe: Up to 3 years of follow-up

Trial details

NCT IDNCT07279207

SponsorIlya Lukin

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12

Contact for this trial

Ilya B. Lukin, MD, PhD

+7 906 656 2630 prlukin@gmail.com

View on ClinicalTrials.gov More Atrial Fibrillation trials